Literature DB >> 15013990

Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.

Michael Schultz1, Ulrike G Strauch, Hans-Jörg Linde, Sonja Watzl, Florian Obermeier, Claudia Göttl, Nadja Dunger, Nicole Grunwald, Jürgen Schölmerich, Heiko C Rath.   

Abstract

Escherichia coli strain Nissle 1917 (EcN) is as effective in maintaining remission in ulcerative colitis as is treatment with mesalazine. This study aims to evaluate murine models of acute and chronic intestinal inflammation to study the antiinflammatory effect of EcN in vivo. Acute colitis was induced in mice with 2% dextran-sodium sulfate (DSS) in drinking water. EcN was administered from day -2 to day +7. Chronic colitis was induced by transfer of CD4(+) CD62L(+) T lymphocytes from BALB/c mice in SCID mice. EcN was administered three times/week from week 1 to week 8 after cell transfer. Mesenteric lymph node (MLN) cytokine secretion (of gamma interferon [IFN-gamma], interleukin 5 [IL-5], IL-6, and IL-10) was measured by enzyme-linked immunosorbent assay. Histologic sections of the colon were analyzed by using a score system ranging from 0 to 4. Intestinal contents and homogenized MLN were cultured, and the number of E. coli-like colonies was determined. EcN was identified by repetitive extragenic palindromic (REP) PCR. EcN administration to DSS-treated mice reduced the secretion of proinflammatory cytokines (IFN-gamma, 32,477 +/- 6,377 versus 9,734 +/- 1,717 [P = 0.004]; IL-6, 231 +/- 35 versus 121 +/- 17 [P = 0.02]) but had no effect on the mucosal inflammation. In the chronic experimental colitis of the transfer model, EcN ameliorated the intestinal inflammation (histology score, 2.7 +/- 0.2 versus 1.9 +/- 0.3 [P = 0.02]) and reduced the secretion of proinflammatory cytokines. Translocation of EcN and resident E. coli into MLN was observed in the chronic colitis model but not in healthy controls. Administration of EcN ameliorated acute and chronic experimental colitis by modifying proinflammatory cytokine secretion but had no influence on the acute DSS-induced colitis. In this model, preexisting colitis was necessary for translocation of EcN and resident E. coli into MLN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013990      PMCID: PMC371200          DOI: 10.1128/cdli.11.2.372-378.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  39 in total

Review 1.  Probiotics in the management and prevention of atopy.

Authors:  John Bienenstock; Ryan E Wiley; G Scott Neigh; Susan Waserman; Paul Keith
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

2.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 3.  Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea.

Authors:  F Cremonini; S Di Caro; E C Nista; F Bartolozzi; G Capelli; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2002-08       Impact factor: 8.171

Review 4.  Intestinal barrier function.

Authors:  Daniel C Baumgart; Axel U Dignass
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-11       Impact factor: 4.294

5.  Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora.

Authors:  Yingzi Cong; Casey T Weaver; Audrey Lazenby; Charles O Elson
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

6.  Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment.

Authors:  L A Dieleman; M S Goerres; A Arends; D Sprengers; C Torrice; F Hoentjen; W B Grenther; R B Sartor
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

7.  Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice.

Authors:  Michael Schultz; Claudia Veltkamp; Levinus A Dieleman; Wetonia B Grenther; Pricilla B Wyrick; Susan L Tonkonogy; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2002-03       Impact factor: 5.325

Review 8.  Anti-interleukin-6 therapy for Crohn's disease.

Authors:  H Ito
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease.

Authors:  M F Neurath; B Weigmann; S Finotto; J Glickman; E Nieuwenhuis; H Iijima; A Mizoguchi; E Mizoguchi; J Mudter; P R Galle; A Bhan; F Autschbach; B M Sullivan; S J Szabo; L H Glimcher; R S Blumberg
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

View more
  42 in total

1.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 2.  Probiotics manipulate host cytokine response and induce antimicrobial peptides.

Authors:  I Trebichavský; I Splíchal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

3.  Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.

Authors:  Benoit Foligne; Sophie Nutten; Corinne Grangette; Véronique Dennin; Denise Goudercourt; Sabine Poiret; Joelle Dewulf; Dominique Brassart; Annick Mercenier; Bruno Pot
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

4.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 5.  Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.

Authors:  Franco Scaldaferri; Viviana Gerardi; Francesca Mangiola; Loris Riccardo Lopetuso; Marco Pizzoferrato; Valentina Petito; Alfredo Papa; Jovana Stojanovic; Andrea Poscia; Giovanni Cammarota; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

6.  A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation.

Authors:  Rose A Whelan; Sebastian Rausch; Friederike Ebner; Dorothee Günzel; Jan F Richter; Nina A Hering; Jörg-Dieter Schulzke; Anja A Kühl; Ahmed Keles; Pawel Janczyk; Karsten Nöckler; Lothar H Wieler; Susanne Hartmann
Journal:  Mol Ther       Date:  2014-07-02       Impact factor: 11.454

7.  A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.

Authors:  Shahram Lavasani; Balik Dzhambazov; Mehrnaz Nouri; Frida Fåk; Sophia Buske; Göran Molin; Henrik Thorlacius; Jan Alenfall; Bengt Jeppsson; Björn Weström
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 8.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

9.  The noncommensal bacterium Methylococcus capsulatus (Bath) ameliorates dextran sulfate (Sodium Salt)-Induced Ulcerative Colitis by influencing mechanisms essential for maintenance of the colonic barrier function.

Authors:  Charlotte R Kleiveland; Lene T Olsen Hult; Signe Spetalen; Magne Kaldhusdal; Trine Eker Christofferesen; Oskar Bengtsson; Odd Helge Romarheim; Morten Jacobsen; Tor Lea
Journal:  Appl Environ Microbiol       Date:  2012-10-12       Impact factor: 4.792

10.  Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy.

Authors:  Erika Mileti; Gianluca Matteoli; Iliyan D Iliev; Maria Rescigno
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.